Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Whatever the outcome considered, adjusted results showed a highly significant difference ( P ≤0.005) in the incidence of inhibitors among the groups receiving the three most used products between 2001 and 2016.

also in 132,142 other papers